Conference call with CEO Chang and CMO Roberts on March 26 at 2:30 pm hosted by JPMorgan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics: Buy Rating Backed by Promising Pipeline Developments and Strong Financial Position
- Allogene Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
- Allogene Therapeutics management to meet virtually with Truist
- Allogene Therapeutics’ Earnings Call Highlights Progress
- Promising Pipeline and Upcoming Data Releases Drive Buy Rating for Allogene Therapeutics